Sanuwave Health (NASDAQ:SNWV) Cut to Buy at Wall Street Zen

Key Points

• Wall Street Zen downgraded Sanuwave Health from a "strong-buy" to a "buy" rating, while other analysts maintained a positive outlook with a consensus rating of "Buy" and an average price target of $55.00.
• Sanuwave Health's shares are currently trading at $37.88, reflecting a decline of 2.0% recently, with a fifty-two week high of $46.58 and a low of $5.21.
• The company reported earnings of $0.01 EPS for the last quarter, surpassing analyst expectations, and had a revenue of $10.16 million, meeting estimates.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Sunday.

A number of other analysts also recently weighed in on the stock. Northland Capmk upgraded shares of Sanuwave Health to a "strong-buy" rating in a research report on Wednesday, September 3rd. Roth Capital raised their target price on shares of Sanuwave Health from $54.00 to $55.00 and gave the stock a "buy" rating in a report on Friday, August 22nd. Finally, Northland Securities began coverage on shares of Sanuwave Health in a report on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $55.00.

Sanuwave Health Stock Performance

Shares of NASDAQ:SNWV traded down $0.04 during mid-day trading on Friday, reaching $36.98. The stock had a trading volume of 29,349 shares, compared to its average volume of 39,591. The company has a market cap of $316.92 million, a price-to-earnings ratio of -4.48 and a beta of 1.39. The stock has a 50 day moving average of $37.89. Sanuwave Health has a twelve month low of $5.63 and a twelve month high of $46.58.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10. The firm had revenue of $10.16 million during the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Trading of Sanuwave Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc acquired a new stake in shares of Sanuwave Health in the second quarter valued at approximately $26,000. BNP Paribas Financial Markets acquired a new stake in shares of Sanuwave Health in the second quarter valued at approximately $46,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Sanuwave Health in the first quarter valued at approximately $47,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sanuwave Health in the second quarter valued at approximately $52,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Sanuwave Health in the second quarter valued at approximately $102,000. 42.53% of the stock is currently owned by institutional investors and hedge funds.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.